quantisnow
FeedTopReportsPricing
⌘K
Live feed
15:00:00·6d
PRRelease
Immatics N.V. logo

PRAME-directed Cell Therapy Using Immatics' TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma

IMTX· Immatics N.V.
Health Care
Original source

Companies

  • IMTX
    Immatics N.V.
    Health Care

Recent analyst ratings

  • Mar 16UpdateJefferies-
  • Sep 18UpdateGuggenheim$16.00
  • May 28UpdateDeutsche Bank$10.00
  • Oct 7UpdatePiper Sandler$19.00
  • Nov 2UpdateCantor Fitzgerald-
  • Mar 31UpdateMizuho$12.00

Related

  • SEC2d
    SEC Form 6-K filed by Immatics N.V.
  • PR2d
    Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
  • SEC6d
    SEC Form 6-K filed by Immatics N.V.
  • INSIDER36d
    SEC Form 3 filed by new insider Reinhardt Carsten Alexander Johannes
  • INSIDER36d
    SEC Form 3 filed by new insider Britten Cedrik Michael
  • INSIDER36d
    SEC Form 3 filed by new insider Sturchio Edward A Jr
  • INSIDER36d
    SEC Form 3 filed by new insider Silverstein Jordan Zeik
  • INSIDER36d
    SEC Form 3 filed by new insider Singh Jasuja Harpreet
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022